Raymond James & Associates Viking Therapeutics, Inc. Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

A detailed history of Raymond James & Associates transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 308,446 shares of VKTX stock, worth $16.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

308,446

Previous 245,240 25.77%

Holding current value

$16.7 Million

Previous $20.1 Million 18.69%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$47.39 - $80.2 $3 Million - $5.07 Million	63,206 Added 25.77%	308,446 $16.4 Million
Q1 2024 Apr 22, 2024	BUY	$17.4 - $94.5 $1.87 Million - $10.2 Million	107,657 Added 78.25%	245,240 $20.1 Million
Q4 2023 Jan 16, 2024	BUY	$9.24 - $19.64 $636,830 - $1.35 Million	68,921 Added 100.38%	137,583 $2.56 Million
Q3 2023 Oct 24, 2023	BUY	$10.92 - $16.0 $1,638 - $2,400	150 Added 0.22%	68,662 $760,000
Q2 2023 Jul 25, 2023	BUY	$14.84 - $24.79 $334,508 - $558,791	22,541 Added 49.03%	68,512 $1.11 Million
Q1 2023 Apr 14, 2023	SELL	$8.08 - $17.33 $386,999 - $830,037	-47,896 Reduced 51.03%	45,971 $765,000
Q4 2022 Feb 08, 2023	SELL	$2.72 - $9.4 $29,541 - $102,093	-10,861 Reduced 10.37%	93,867 $882,000
Q3 2022 Oct 25, 2022	SELL	$2.55 - $3.89 $21,116 - $32,213	-8,281 Reduced 7.33%	104,728 $285,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $22,665 - $33,837	-10,742 Reduced 8.68%	113,009 $327,000
Q1 2022 May 11, 2022	SELL	$3.0 - $4.88 $40,392 - $65,704	-13,464 Reduced 9.81%	123,751 $371,000
Q4 2021 Feb 08, 2022	SELL	$4.6 - $6.72 $524,956 - $766,893	-114,121 Reduced 45.41%	137,215 $631,000
Q3 2021 Nov 02, 2021	SELL	$5.58 - $7.04 $45,114 - $56,918	-8,085 Reduced 3.12%	251,336 $1.58 Million
Q2 2021 Aug 11, 2021	SELL	$5.19 - $6.73 $738,583 - $957,739	-142,309 Reduced 35.42%	259,421 $1.55 Million
Q1 2021 May 14, 2021	BUY	$5.74 - $9.67 $621,923 - $1.05 Million	108,349 Added 36.93%	401,730 $2.54 Million
Q4 2020 Feb 12, 2021	SELL	$5.3 - $6.71 $460,755 - $583,333	-86,935 Reduced 22.86%	293,381 $1.65 Million
Q3 2020 Nov 04, 2020	BUY	$5.73 - $8.11 $1,558 - $2,205	272 Added 0.07%	380,316 $2.21 Million
Q2 2020 Jul 28, 2020	BUY	$4.35 - $8.08 $526,289 - $977,566	120,986 Added 46.7%	380,044 $2.74 Million
Q1 2020 Apr 21, 2020	SELL	$3.45 - $7.95 $9,363 - $21,576	-2,714 Reduced 1.04%	259,058 $1.21 Million
Q4 2019 Feb 12, 2020	SELL	$6.38 - $8.73 $454,383 - $621,750	-71,220 Reduced 21.39%	261,772 $2.1 Million
Q3 2019 Nov 07, 2019	SELL	$6.55 - $8.6 $530 - $696	-81 Reduced 0.02%	332,992 $2.29 Million
Q2 2019 Aug 06, 2019	BUY	$7.67 - $10.63 $25,671 - $35,578	3,347 Added 1.02%	333,073 $2.77 Million
Q1 2019 May 06, 2019	BUY	$7.58 - $9.94 $1.25 Million - $1.63 Million	164,457 Added 99.51%	329,726 $3.28 Million
Q4 2018 Feb 11, 2019	BUY	$7.16 - $16.21 $158,393 - $358,597	22,122 Added 15.45%	165,269 $1.26 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $1.39 Million - $2.81 Million	143,147 New	143,147 $2.49 Million

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.15B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Viking Therapeutics, Inc. Transaction History